Uwe Schoenbeck, Ph.D.

Uwe Schoenbeck, Ph.D., is a venture partner at Canaan Partners, an early-stage venture capital firm that invests in entrepreneurs with visionary ideas. At Canaan, Dr. Schoenbeck helps drive new investments and company creation by bringing deep scientific and pharmaceutical perspectives, while also serving as a valuable resource to companies across the firm’s existing biopharma portfolio. Prior to joining Canaan, Dr. Schoenbeck served as Senior Vice President and Chief Scientific Officer Emerging Science & Innovation (ES&I) in Pfizer’s Worldwide Development & Medical (WRDM) division, where he worked to harness external breakthrough science, assets, and technologies by leveraging a broad range of partnering vehicles. Before joining the Pfizer, he served as Vice President, Emerging R&D Innovation for Wyeth and Vice President, Cardiovascular Research for Boehringer Ingelheim. Dr. Schoenbeck received his Ph.D. from the University of Kiel in Germany and completed postdoctoral training in the Division of Cardiovascular Medicine at Brigham & Women’s Hospital at Harvard before joining as a faculty member.